Biotechnology company developing antibody therapeutics for inflammation, autoimmune diseases, and cancer.
AnaptysBio, Inc., based in San Diego, California, is a clinical-stage biotechnology firm specializing in the development of therapeutic product candidates aimed at treating inflammation and immuno-oncology conditions. The company's innovative pipeline includes several promising products designed to address significant medical needs.
Among its key products is Imsidolimab, an antibody targeting the interleukin-36 receptor (IL-36R) intended for treating various dermatological inflammatory diseases. AnaptysBio also focuses on Rosnilimab, an anti-PD-1 agonist antibody program designed to enhance PD-1 signaling, thereby suppressing T-cell driven inflammatory diseases in humans. Additionally, ANB032, another antibody in its portfolio, targets BTLA modulation to address inflammatory conditions associated with immune cell dysregulation.
AnaptysBio's research and development efforts are bolstered by collaborations with major pharmaceutical companies, including GlaxoSmithKline and Bristol-Myers Squibb. These partnerships facilitate the advancement of various antibody programs through preclinical and clinical stages, aiming to deliver innovative treatments to patients.
Founded in 2005 as Anaptys Biosciences, Inc., the company rebranded as AnaptysBio, Inc. in July 2006. AnaptysBio continues to expand its portfolio and capabilities in biotechnology, leveraging strategic collaborations and cutting-edge research to drive advancements in the treatment of inflammatory and immuno-oncology disorders.